Tubulis
Tubulis is a biotech company leveraging a collaborative network of experts in chemistry, antibody technologies, and clinical oncology to advance drug development.
Classification
Profile
Funding
Funding details not yet available.
Leverages a collaborative network of expertise in chemistry, antibody technologies, and clinical oncology to advance drug development.
Pharmaceutical and biotech companies requiring specialized bioconjugation and antibody technology services.
Likely licensing deals, partnerships, or milestone payments, though specific revenue streams are not detailed in the snippets.
Direct engagement through a strong scientific and entrepreneurial network and collaborative partnerships.
Collaborative network with expertise in chemistry, antibody technologies, bioconjugation, business, drug development, and clinical oncology.
R&D and operational costs associated with maintaining a specialized scientific network and drug development capabilities.
Strong scientific and entrepreneurial network, specialized team expertise, and a site at IZB in Munich.
Integrating scientific expertise in bioconjugation and antibody technologies to support drug development processes.
Relationships built through a strong scientific and entrepreneurial network and collaborative expertise.
Competes via a unique collaborative network combining chemistry, antibody tech, and oncology expertise.
Need for specialized expertise in antibody technologies and bioconjugation for effective drug development.
- Diversify Partner Portfolio - target mid-size biotech firms and emerging markets (Asia-Pacific) to reduce concentration risk on a few lar
- Leverage high-DAR advantage to secure more first-in-class licensing deals, especially for targets where payload potency is critical (e.g.
Funding Validation - €128 M Series B2 (2024) and €308 M Series C (2025) demonstrate strong investor confidence and provide the capital neede · Regulatory Milestones - FDA Fast-Track for TUB-040 and Phase 2 progression of TUB-030 reduce development risk and increase valuation multipl · Industry Recognition - Named a “Fierce 15” biotech (2024) and fe
Team details not yet available.
No investors recorded yet.